Thirty five generic drugmakers around the world will make cheap versions of Pfizer Inc's PFE.N highly effective COVID-19 oral antiviral Paxlovid to supply the treatment in 95 poorer countries, the UN-backed Medicines Patent Pool (MPP) said on Thursday.

 

Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries. They have been working since then to select the drugmakers they will license.

 

Paxlovid is expected to be an important tool in the fight against COVID-19 after it reduced hospitalizations in high-risk patients by around 90% in a clinical trial. The results were significantly better than those for Merck & Co's MRK.N rival antiviral pill molnupiravir in its clinical trial.

 

Pfizer and Merck both struck deals with MPP to allow generic versions of their new drugs in some parts of the world, a rarity for pharmaceutical companies that usually fiercely protect their treatments over the life of their patents.

 

Merck, on its own and through the MPP license, has deals with dozens of drugmakers to make its pill and generic versions are already available in some countries.

 

But Pfizer and MPP do not expect any of generic drugmakers to be able to manufacture significant supplies of Paxlovid before the end of the year.

 

The 35 companies that will produce versions of Paxlovid or its active ingredient are based in 12 different countries, the MPP said. They include some of the world's largest generic manufacturers like Israel's Teva Pharmaceutical Industries TEVA.TA, India-based Sun Pharmaceutical Industries SUN.NS, and US-based Viatris Inc VTRS.O.

 

Six of the companies will make the main ingredient for the drug, nine plan to turn that into a finished product and the remaining companies will do both.

 

Paxlovid is a two-drug treatment that pairs a new compound, nirmatrelvir, with the older antiviral ritonavir, which is already available as a generic.

 

Pfizer will not receive royalties from the sale of the generic versions of its drug whileCOVID-19 remains classified as a "Public Health Emergency of International Concern" by the World Health Organization.

 

Following the pandemic period, sales to low-income countries will remain royalty free, lower-middle-income countries and upper-middle-income countries will be subject to a 5% royalty for sales to the public sector and a 10% royalty for sales to the private sector, MPP said.

 

Pfizer has said it plans to produce at least 120 million treatment courses of the treatment this year, well short of its estimate of the 2022 market for antiviral pills of 250 million people globally.

 

The company is also expected to provide around 10 million courses Paxlovid it produces to low- and middle-income countries this year, according to an official with the Global Fund, a healthcare NGO working to buy the pills from the drugmaker.